Richards Thomas B, Henley S Jane, Puckett Mary C, Weir Hannah K, Huang Bin, Tucker Thomas C, Allemani Claudia
Division of Cancer Prevention and Control, National Center for Chronic Disease Prevention and Health Promotion, Centers for Disease Control and Prevention, Atlanta, Georgia.
Department of Biostatistics, College of Public Health, University of Kentucky, Lexington, Kentucky.
Cancer. 2017 Dec 15;123 Suppl 24(Suppl 24):5079-5099. doi: 10.1002/cncr.31029.
Results from the second CONCORD study (CONCORD-2) indicated that 5-year net survival for lung cancer was low (range, 10%-20%) between 1995 and 2009 in most countries, including the United States, which was at the higher end of this range.
Data from CONCORD-2 were used to analyze net survival among patients with lung cancer (aged 15-99 years) who were diagnosed in 37 states covering 80% of the US population. Survival was corrected for background mortality using state-specific and race-specific life tables and age-standardized using International Cancer Survival Standard weights. Net survival was estimated for patients diagnosed between 2001 and 2003 and between 2004 and 2009 at 1, 3, and 5 years after diagnosis by race (all races, black, and white); Surveillance, Epidemiology, and End Results Summary Stage 2000; and US state.
Five-year net survival increased from 16.4% (95% confidence interval, 16.3%-16.5%) for patients diagnosed 2001-2003 to 19.0% (18.8%-19.1%) for those diagnosed 2004-2009, with increases in most states and among both blacks and whites. Between 2004 and 2009, 5-year survival was lower among blacks (14.9%) than among whites (19.4%) and ranged by state from 14.5% to 25.2%.
Lung cancer survival improved slightly between the periods 2001-2003 and 2004-2009 but was still low, with variation between states, and persistently lower survival among blacks than whites. Efforts to control well established risk factors would be expected to have the greatest impact on reducing the burden of lung cancer, and efforts to ensure that all patients receive timely and appropriate treatment should reduce the differences in survival by race and state. Cancer 2017;123:5079-99. Published 2017. This article is a U.S. Government work and is in the public domain in the USA.
第二项CONCORD研究（CONCORD-2）的结果表明，在1995年至2009年期间，包括美国在内的大多数国家肺癌的5年净生存率较低（范围为10% - 20%），美国处于该范围的较高端。
使用CONCORD-2的数据来分析在覆盖美国80%人口的37个州中确诊的肺癌患者（年龄在15 - 99岁）的净生存率。使用特定州和特定种族的生命表对生存情况进行背景死亡率校正，并使用国际癌症生存标准权重进行年龄标准化。对2001年至2003年以及2004年至2009年期间确诊的患者，按种族（所有种族、黑人、白人）、监测、流行病学和最终结果总结阶段2000以及美国州别，估计诊断后1年、3年和5年的净生存率。
2001 - 2003年确诊患者的5年净生存率从16.4%（95%置信区间，16.3% - 16.5%）升至2004 - 2009年确诊患者的19.0%（18.8% - 19.1%），大多数州以及黑人和白人的生存率均有所上升。2004年至2009年期间，黑人的5年生存率（14.9%）低于白人（19.4%），各州范围为14.5%至25.2%。
2001 - 2003年至2004 - 2009年期间肺癌生存率略有改善，但仍较低，各州之间存在差异，黑人的生存率持续低于白人。控制已明确的危险因素的努力预计对减轻肺癌负担影响最大，确保所有患者获得及时和适当治疗的努力应能减少种族和州别之间的生存差异。《癌症》2017年；123:5079 - 99。2017年发表。本文为美国政府作品，在美国属于公共领域。
